Semaglutide + Cagrilintide (CagriSema) Research | QSC
QSC · RESEARCH CATALOG
Semaglutide + Cagrilintide (CagriSema) Research Combination GLP-1R Monoagonist + AMY1R Amylin Agonist · Dual Pathway Metabolic Research · ≥99% HPLC · Janoshik COA
CagriSema (Semaglutide + Cagrilintide) is Novo Nordisk’s Phase 3 fixed-dose combination targeting both GLP-1R (Semaglutide) and AMY1R amylin receptor (Cagrilintide). Phase 2 trial data showed −15.6% weight reduction at 32 weeks — exceeding Semaglutide monotherapy, with complementary mechanisms. QSC supplies both compounds individually at ≥99% HPLC with Janoshik independent COA for in vitro research.
CagriSema is the research/clinical name for the Semaglutide + Cagrilintide fixed-dose combination developed by Novo Nordisk. Semaglutide activates GLP-1R; Cagrilintide activates AMY1R (amylin receptor). Phase 2 results showed −15.6% weight reduction at 32 weeks — exceeding Semaglutide monotherapy at equivalent timepoints. Now in Phase 3 (REDEFINE program). QSC supplies both separately at ≥99% HPLC with Janoshik COA. Research use only.
How does Cagrilintide differ from Semaglutide?
Semaglutide acts on GLP-1R (glucagon-like peptide 1 receptor) — primarily hypothalamic satiety signaling. Cagrilintide acts on AMY1R (amylin receptor) — primarily hindbrain/brainstem satiety signaling. Different receptor systems, different anatomical sites of action, additive weight reduction when combined. Long-acting amylin agonist class is distinct from the GLP-1 agonist class.
Does QSC stock Cagrilintide?
Yes — QSC stocks Cagrilintide at ≥99% HPLC with Janoshik independent COA. One of the few US suppliers to stock this compound. Verifiable at verify.janoshik.com. Research use only.
Buy Semaglutide + Cagrilintide (CagriSema) Research Combination Components
Both compounds available at ≥99% HPLC · Janoshik Independent COA · verify.janoshik.com
Research Use Only: All QSC products sold strictly for in vitro laboratory research. Not for human or veterinary use. Information on this page is educational and does not constitute medical advice.